´Ù¹ß¼º °æÈ­Áõ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
Multiple Sclerosis Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography
»óǰÄÚµå : 1672999
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,197,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,640,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,772,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

´Ù¹ß¼º °æÈ­Áõ Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2025³â¿¡ 313¾ï 9,000¸¸ ´Þ·¯, 2032³â¿¡´Â 418¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â°£ ¿¬Æò±Õ 4.2% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 313¾ï 9,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 4.20% 2032³â ±Ý¾× ¿¹Ãø 418¾ï 9,000¸¸ ´Þ·¯
±×¸². 2025³â Áö¿ªº° ´Ù¹ß¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²(%)
Multiple Sclerosis Therapeutics Market-IMG1

´Ù¹ß¼º °æÈ­Áõ(MS)Àº ÁßÃ߽Űæ°è(CNS)¸¦ ħ¹üÇÏ´Â ¸¸¼º ÀÚ°¡¸é¿ªÁúȯÀÔ´Ï´Ù. ´Ù¹ß¼º °æÈ­ÁõÀº ÁßÃ߽Űæ°è(CNS)ÀÇ ½Å°æ¼¶À¯¸¦ µÑ·¯½Î°í ÀÖ´Â º¸È£¸·ÀÎ ¹Ì¿¤¸°À» ¸é¿ª°è°¡ °ø°ÝÇÏ¿© ¹ßº´ÇÕ´Ï´Ù. ±× °á°ú, ³ú¿Í ½ÅüÀÇ ´Ù¸¥ ºÎÀ§ »çÀÌÀÇ Á¤º¸ Àü´Þ¿¡ Àå¾Ö°¡ »ý±é´Ï´Ù. ÁßÃ߽Űæ°è º´º¯ÀÇ ¼ö¿Í À§Ä¡¿¡ µû¶ó Áõ»óÀº °æÁõºÎÅÍ ÁßÁõ±îÁö ´Ù¾çÇÕ´Ï´Ù. ÀϹÝÀûÀÎ Áõ»óÀ¸·Î´Â ÇǷΰ¨, »çÁöÀÇ ¼è¾à°¨ ¹× ¸¶ºñ, ÇùÀÀ·Â ¹× ±ÕÇü°¨°¢ ÀúÇÏ, ½Ã·ÂÀå¾Ö, ÀÎÁö±â´É Àå¾Ö µîÀÌ ÀÖÀ¸¸ç, MSÀÇ Ä¡·á¹ýÀº È®¸³µÇ¾î ÀÖÁö ¾ÊÁö¸¸ ÀÎÅÍÆä·Ð, ±Û¶óƼ¶ó¸Ó ¾Æ¼¼Å×ÀÌÆ®, ´ÜÀÏŬ·ÐÇ×ü, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå µîÀÇ ¾à¹°¿ä¹ýÀ¸·Î Áúº´ÀÇ Áõ»óÀ» ¾ïÁ¦Çϰí ÁøÇàÀ» ´ÊÃß´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. Áúº´ÀÇ Áõ»óÀ» ¾ïÁ¦Çϰí ÁøÇàÀ» ´ÊÃâ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è ´Ù¹ß¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¼±Áø±¹°ú °³¹ßµµ»ó±¹ ¸ðµÎ¿¡¼­ ´Ù¹ß¼º °æÈ­Áõ À¯º´·ü Áõ°¡, °í·É Àα¸ Áõ°¡, ´Ù¹ß¼º °æÈ­Áõ¿¡ ´ëÇÑ »õ·Ó°í Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎ, ÀÇ·áºñ ±ÞÁõ, »óȯ Á¦µµ °¡¿ë¼º µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ´Ù¹ß¼º °æÈ­Áõ Ä¡·á¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ´Ù¹ß¼º °æÈ­Áõ Ä¡·á¸¦ À§ÇÑ ¸ÂÃãÇü ÀǾàǰÀÇ ÃâÇö, ´Ù¹ß¼º °æÈ­Áõ Ä¡·á¸¦ À§ÇÑ º´¿ë¿ä¹ý, ÁÖÀÔ¿ä¹ý, °æ±¸¿ë ¾à¹°ÀÇ Ã¤Åà Ȯ´ë´Â ½ÃÀå ¼ºÀåÀÇ ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ ´Ù¹ß¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.

¼¼°è ´Ù¹ß¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀ» ±â¾÷ ¼Ò°³, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

Á¶»ç ´ë»ó ÁÖ¿ä ±â¾÷À¸·Î´Â Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS, CELGENE µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è ´Ù¹ß¼º °æÈ­Áõ Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ´Ù¹ß¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ´Ù¹ß¼º °æÈ­Áõ Ä¡·á ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦5Àå ¼¼°èÀÇ ´Ù¹ß¼º °æÈ­Áõ Ä¡·á ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ ´Ù¹ß¼º °æÈ­Áõ Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ ´Ù¹ß¼º °æÈ­Áõ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦8Àå °æÀï ±¸µµ

Á¦9Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

Á¦10Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Multiple Sclerosis Therapeutics Market is estimated to be valued at USD 31.39 Bn in 2025 and is expected to reach USD 41.89 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 31.39 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 4.20% 2032 Value Projection: USD 41.89 Bn
Figure. Multiple Sclerosis Therapeutics Market Share (%), By Region 2025
Multiple Sclerosis Therapeutics Market - IMG1

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.

Market Dynamics:

Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.

Key features of the study:

This report provides in-depth analysis of the global multiple sclerosis therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2020-2032, (USD Bn)

5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2020-2032, (USD Bn)

6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2020-2032, (USD Bn)

7. Global Multiple Sclerosis Therapeutics Market, By Region, 2020 - 2032, (USD Bn)

8. Competitive Landscape

9. Analyst Recommendations

10. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â